TB Drug Fighting Resistant Strains Wins Europe Approval
This article is for subscribers only.
Otsuka Pharmaceutical Co. won approval to sell its delamanid tuberculosis drug in Europe, one of the first new treatments in 50 years for the deadly infectious disease.
The drug gained marketing clearance from the European Commission for use in a combination therapy for pulmonary multidrug-resistant TB in adult patients , Tokyo-based Otsuka said in a statement. The drug, which will be sold under brand name Deltyba, will begin selling in Germany in four to six weeks, Katsunori Hashiba, a spokesman at Otsuka, said today.